KALC 2025

Session VII (C).
Satellite Symposium I (A).		Room A (Grand Ballroom 3)
Date & Time	November 6(Thu), 08:30-09:10
Chair(s)	TBD
Speaker	TBD TBD

Session VII (C).
Session I (A). Lung cancer and risk factors		Room A (Grand Ballroom 3)
Date & Time	November 6(Thu), 09:20-10:20
Chair(s)	Sei-Hoon Yang (Wonkwang Univ., Korea), Adam Edward Lang (James E. Van Zandt VA Medical Center, USA)
Speaker	09:20-09:40 Update on the smoking cessation at lung examination collaboration trials Adam Edward Lang (James E. Van Zandt VA Medical Center, USA) 09:40-10:00 A legal and epidemiological consideration of the causal relationship between tobacco and lung cancer Sun Ha Jee (Yonsei Univ., Korea) 10:00-10:20 Climate change-fueled natural disasters and the Impacts on lung cancer care Roselle De Guzman (Manila Central University-FDT Medical Foundation Hospital, Philippines)

Session VII (C).
Session II (A). Partnering for life: Creating a seamless journey together		Room A (Grand Ballroom 3)
Date & Time	November 6(Thu), 10:35-11:35
Chair(s)	Si Yeol Song (Univ. of Ulsan, Korea), Jeong Eun Lee (Chungnam National Univ., Korea)
Speaker	10:35-10:55 Educate, empower, engage: Underscoring the value of continuity of care Thomas Newsom-Davis (Chelsea & Westminster Hospital, UK) 10:55-11:15 Toward timely integration of palliative care: Current status of palliative care and advance care planning in Korea Yu Jung Kim (Seoul National Univ., Korea) 11:15-11:35 The heart of care: Empowering lung cancer patients through oncology nursing support Mary Duffy (Peter MacCallum Cancer Centre, Australia)

Session VII (C).
Plenary Session I.		Room A+B+C (Grand Ballroom)
Date & Time	November 6(Thu), 11:50-12:30
Chair(s)	Jin Hyoung Kang (The Catholic Univ. of Korea, Korea)
Speaker	11:50-12:30 New promises and challenges in the treatment of advanced NSCLC Solange Peters (Centre Hospitalier Universitaire Vaudois, Switzerland)

Session VII (C).
Luncheon Symposium I.		Room A+B+C (Grand Ballroom)
Date & Time	November 6(Thu), 12:30-13:10
Chair(s)	TBD
Speaker	12:30-13:10 TBD TBD

Session VII (C).
Session III (A). Thymic epithelial tumors: Multidisciplinary approach		Room A (Grand Ballroom 3)
Date & Time	November 6(Thu), 13:30-14:30
Chair(s)	Jin Mo Goo (Seoul National Univ., Korea), Sung Ho Moon (National Cancer Center, Korea)
Speaker	13:30-13:45 Imaging diagnosis and staging of thymoma Yura Ahn (Univ. of Ulsan, Korea) 13:45-14:00 Thymoma and thymic carcinoma: Do different histologies require different surgical strategies? Jae Kwang Yun (Univ. of Ulsan, Korea) 14:00-14:15 Postoperative radiotherapy in thymic tumors: Recent updates or changes Soo Yoon Sung (The Catholic Univ. of Korea, Korea) 14:15-14:30 Update on systemic therapy in thymic epithelial tumors Seoyoung Lee (Yonsei Univ., Korea)

Session VII (C).
Session IV (A). The evolving landscape of lung cancer surgery		Room A (Grand Ballroom 3)
Date & Time	November 6(Thu), 14:45-15:45
Chair(s)	Deog Gon Cho (The Catholic Univ. of Korea, Korea), Wentao Fang (Shanghai Chest Hospital, Shanghai Jiao Tong University , China)
Speaker	14:45-15:00 Wedge resection versus segmentectomy for peripherally-located solid stage IA1–2 NSCLC: Are they oncologically equivalent? Chang Young Lee (Yonsei Univ., Korea) 15:00-15:15 Knowledge gaps in segmentectomy: What remains to be clarified Hisashi Saji (Tokyo Medical Univ, Japan) 15:15-15:30 Is surgery more challenging after neoadjuvant chemoimmunotherapy: Myth or Reality? In Kyu Park (Seoul National Univ., Korea) 15:30-15:45 The evolving role of robotic surgery in lung cancer: Toward less invasive or more advanced Hyun Koo Kim (Korea Univ., Korea)

Session VII (C).
Satellite Symposium II (A).		Room A (Grand Ballroom 3)
Date & Time	November 6(Thu), 16:00-16:40
Chair(s)	TBD
Speaker	TBD TBD

Session VII (C).
Session I (B). Advanced radiation techniques and technologies		Room B (Grand Ballroom 2)
Date & Time	November 6(Thu), 09:20-10:20
Chair(s)	Hong-Gyun Wu (Seoul National Univ., Korea), Jiraporn Setakornnukul (Siriraj Hospital, Mahidol University, Thailand)
Speaker	09:20-09:35 Physical principles and radiobiological characteristics of particle therapy Yu-Wen Hu (Taipei Veterans General Hospital, Taiwan) 09:35-09:50 Role of particle therapy in early-stage non-small cell lung cancer Masatoshi Nakamura (University of Tsukuba Hospital, Japan) 09:50-10:05 Particle therapy in locally advanced lung cancer: Current evidence and future perspectives Yang-Gun Suh (National Cancer Center, Korea) 10:05-10:20 The integration of immunotherapy and particle therapy Jiraporn Setakornnukul (Siriraj Hospital, Mahidol University, Thailand)

Session VII (C).
Session II (B). Latest trends in biomarker-based precision medicine (KASTT)		Room B (Grand Ballroom 2)
Date & Time	November 6(Thu), 10:35-11:35
Chair(s)	Yoon Soo Chang (Yonsei Univ., Korea), Yasir Y. Elamin (University of Texas MD Anderson Cancer Center, USA)
Speaker	10:35-10:50 Targeted therapy in early stage NSCLC Cheol Kyu Park (Chonnam National Univ., Korea) 10:50-11:05 Circulating tumor DNA (ctDNA) minimal residual disease (MRD) detection in early stage NSCLC Rina Hui (Centre of Cancer Medicine, University of Hong Kong, Hong Kong, China) 11:05-11:20 Longitudinal tracking of ALK-rearranged NSCLC from plasma using circulating tumor RNA and circulating tumor DNA Yasir Y. Elamin (University of Texas MD Anderson Cancer Center, USA) 11:20-11:35 The current landscape of liquid biopsy in Korea Eun Hye Lee (Yonsei Univ., Korea)

Session VII (C).
Session III (B). ADCs: Current controversies		Room B (Grand Ballroom 2)
Date & Time	November 6(Thu), 13:30-14:30
Chair(s)	Jin Seok Ahn (Sungkyunkwan Univ., Korea), David Planchard (Gustave Roussy Cancer Campus, France)
Speaker	13:30-13:45 The era of antibody drug conjugates in lung cancer: Trick or Threat? David Planchard (Gustave Roussy Cancer Campus, France) 13:45-14:00 Trop2 ADCs: Is there hope or is all is lost? Stephanie Saw (National Cancer Centre Singapore, Singapore) 14:00-14:15 Biomarkers for ADCs: IHC and Beyond Jii Bum Lee (Yonsei Univ., Korea) 14:15-14:30 Emerging ADCs: The next generation Molly Li (The Chinese University of Hong Kong, Hong Kong, China)

Session VII (C).
Session IV (B). Oncogene Addicted NSCLC: Beyond EGFR and ALK		Room B (Grand Ballroom 2)
Date & Time	November 6(Thu), 14:45-15:45
Chair(s)	Tae Min Kim (Seoul National Univ., Korea), Ross Soo (National University Health System, Singapore)
Speaker	14:45-15:05 For ROS1 Fusion NSCLC, Is there still a place for sequential treatment starting with crizotinib? Aaron Tan (National Cancer Centre Singapore, Singapore) 15:05-15:25 HER2 Mutant NSCLC: ADC vs TKI, Challenges Ross Soo (National University Health System, Singapore) 15:25-15:45 KRAS G12C and non-G12C RAS in lung cancer Min Hee Hong (Yonsei Univ., Korea)

Session VII (C).
Satellite Symposium I (C).		Room C (Grand Ballroom 1)
Date & Time	November 6(Thu), 08:40-09:10
Chair(s)	TBD
Speaker	TBD TBD

Session VII (C).
Session I (C). Controversies and future directions of lung cancer screening		Room C (Grand Ballroom 1)
Date & Time	November 6(Thu), 09:20-10:20
Chair(s)	Yeol Kim (National Cancer Center, Korea), Pan-Chyr Yang (National Taiwan University, Taiwan)
Speaker	09:20-09:35 Optimizing screening eligibility with risk-prediction models and biomarkers Yeon Wook Kim (Seoul National Univ., Korea) 09:35-09:50 Enhancing benefits by increasing uptake and adherence Roger Y Kim (University of Pennsylvania, USA) 09:50-10:05 Addressing region- and population-specific needs in Asia Pan-Chyr Yang (National Taiwan University, Taiwan) 10:05-10:20 Lung cancer screening in never smokers Yeun-Chung Chang (National Taiwan University College of Medicine, Taiwan)

Session VII (C).
Session II (C). Nodule management and early diagnostic strategies		Room C (Grand Ballroom 1)
Date & Time	November 6(Thu), 10:35-11:35
Chair(s)	Seung Hun Jang (Hallym Univ., Korea), Jianye Chen (National University Hospital, Singapore)
Speaker	10:35-10:50 Novel technologies for nodule risk stratification Young Sik Park (Seoul National Univ., Korea) 10:50-11:05 Advanced bronchoscopy as a modality of choice for peripheral lung lesions Fabien Maldonado (Vanderbilt University, USA) 11:05-11:20 Management of multifocal adenocarcinomas presenting as subsolid lesions Jianye Chen (National University Hospital, Singapore) 11:20-11:35 Advancing Lung Cancer Screening: Detection and Management of Early-Stage Lung Cancer Jacob Sands (Dana Farber Cancer Institute, USA)

Session VII (C).
Session III (C). Interventional pulmonology		Room C (Grand Ballroom 1)
Date & Time	November 6(Thu), 13:30-14:30
Chair(s)	Young Sik Park (Seoul National Univ., Korea), Masahide Oki (Nagoya Medical Center, Japan)
Speaker	13:30-13:50 Optimizing tissue acquisition with advanced biopsy techniques Dongil Park (Chungnam Univ., Korea) 13:50-14:10 Bronchoscopic intervention for central airway obstruction due to lung cancer Masahide Oki (Nagoya Medical Center, Japan) 14:10-14:30 Management of malignant pleural effusion: From palliation to treatment David Feller-Kopman (Dartmouth University, USA)

Session VII (C).
Session IV (C). Oral Presentation I		Room C (Grand Ballroom 1)
Date & Time	November 6(Thu), 14:45-15:45
Chair(s)	TBD
Speaker	TBD TBD TBD TBD TBD TBD TBD TBD

Session VII (C).
Satellite Symposium II (C).		Room C (Grand Ballroom 1)
Date & Time	November 6(Thu), 16:00-16:40
Chair(s)	TBD
Speaker	TBD TBD

Session VII (C).
Satellite Symposium III (A).		Room A (Grand Ballroom 3)
Date & Time	November 7(Fri), 08:20-09:00
Chair(s)	TBD
Speaker	TBD TBD

Session VII (C).
Session V (A). Novel immunotherapies beyond the PD1 pathway		Room A (Grand Ballroom 3)
Date & Time	November 7(Fri), 09:10-10:10
Chair(s)	Dong-Wan Kim (Seoul National Univ., Korea), Aron Lisberg (University of California, USA)
Speaker	09:10-09:25 Beyond PD-L1 axis inhibition: Where are we going? Aron Lisberg (University of California, USA) 09:25-09:40 Bispecifics and T cell engagers: Fighting against immune desert Jeongmin Seo (Seoul National Univ., Korea) 09:40-09:55 Combining ICIs with ADCs is the way to go? Sun Min Lim (Yonsei Univ., Korea) 09:55-10:10 Cellular therapies: Breaking the glass ceiling? Ben Creelan (H. Lee Moffitt Cancer Center & Research Institute, USA)

Session VII (C).
Session VI (A). Challenges during immunotherapy		Room A (Grand Ballroom 3)
Date & Time	November 7(Fri), 10:25-11:25
Chair(s)	Jae Cheol Lee (Univ. of Ulsan., Korea), Jordi Remon Masip (Institut Gustave Roussy, France)
Speaker	10:25-10:40 Should we exclude immunotherapy in case of advanced NSCLC with oncogenic addiction? Jordi Remon Masip (Institut Gustave Roussy, France) 10:40-10:55 When can or should anti-PD(L)-1 be stopped in advanced NSCLC? Jun Hyeok Lim (Inha Univ., Korea) 10:55-11:10 Is it feasible to restart immunotherapy after severe immune-related toxicity? Jinyong Kim (Sungkyunkwan Univ., Korea) 11:10-11:25 Immunotherapy and brain metastases Thomas John (Peter MacCallum Cancer Centre, Australia)

Session VII (C).
Luncheon Symposium II.		Room A+B+C (Grand Ballroom)
Date & Time	November 7(Fri), 11:40-12:20
Chair(s)	TBD
Speaker	11:40-12:20 TBD TBD

Session VII (C).
Plenary Session II.		Room A+B+C (Grand Ballroom)
Date & Time	November 7(Fri), 12:50-13:30
Chair(s)	Myung Ju Ahn (Sungkyunkwan Univ., Korea)
Speaker	12:50-13:30 Current uses and pitfalls of liquid biopsy in NSCLC Natasha B. Leighl (Princess Margaret Cancer Centre, Canada)

Session VII (C).
Session VII (A). Surgery in the chemoimmunotherapy era: Global perspectives		Room A (Grand Ballroom 3)
Date & Time	November 7(Fri), 13:50-14:50
Chair(s)	Suk Ki Cho (Seoul National Univ., Korea), Alessandro Brunelli (St. James's University Hospital, UK)
Speaker	13:50-14:05 Refining surgical boundaries after neoadjuvant therapy in lung cancer Samina Park (Seoul National Univ., Korea) 14:05-14:20 Optimal nodal management strategies after induction therapy: Scope, challenges, and surgical precision Mong-Wei Lin (National Taiwan University Hospital, Taiwan) 14:20-14:35 Managing pCR in lung cancer: the evolving role of ctDNA in postoperative strategy Jeonghwan Youk (Seoul National Univ., Korea) 14:35-14:50 Real-world surgical outcomes after neoadjuvant chemoimmunotherapy: The European experience Alessandro Brunelli (St. James's University Hospital, UK)

Session VII (C).
Session VIII (A). Stage-Specific considerations and dilemmas		Room A (Grand Ballroom 3)
Date & Time	November 7(Fri), 15:05-16:05
Chair(s)	Gong Yong Jin (Jeonbuk National Univ., Korea), Jong Ho Cho (Sungkyunkwan Univ., Korea)
Speaker	15:05-15:25 Imaging controversies in lung cancer staging Won Gi Jeong (Chonnam National Univ., Korea) 15:25-15:45 Systematic EBUS Staging to guide therapy June hong Ahn (Yeungnam Univ., Korea) 15:45-16:05 Should yp-staging be defined in future editions of the TNM classification system? Young Tae Kim (Seoul National Univ., Korea)

Session VII (C).
Session I (B). Insights into lung cancer pathology		Room B (Grand Ballroom 2)
Date & Time	November 7(Fri), 09:10-10:10
Chair(s)	Jin-Haeng Chung (Seoul National Univ., Korea), Mari Mino-Kenudson (Massachusetts General Hospital, USA)
Speaker	09:10-09:30 Intraoperative evaluations of surgical margins/STAS Mari Mino-Kenudson (Massachusetts General Hospital, USA) 09:30-09:50 Pitfalls in intraoperative evaluations: Benign versus malignant Dong Hoon Shin (Pusan National Univ., Korea) 09:50-10:10 Tissue is the issue: Maximizing molecular insights from small biopsy and cytology samples Yeoun Eun Sung (The Catholic Univ. of Korea, Korea)

Session VII (C).
Session VI (B). Unlocking lung cancer: Biological discoveries		Room B (Grand Ballroom 2)
Date & Time	November 7(Fri), 10:25-11:25
Chair(s)	Seung Yeon Ha (Gachon Univ., Korea), In-Jae Oh (Chonnam National Univ., Korea)
Speaker	10:25-10:40 Decoding systemic inflammation in lung cancer: Toward precision immuno-oncology Jae-Ho Cho (Chonnam National Univ., Korea) 10:40-10:55 Integrative proteogenomics identifies non-small cell lung cancer subtypes associated with chromosomal instability and enhanced kinase activity Joon-Yong An (Korea Univ., Korea) 10:55-11:10 Lepidic adenocarcinoma emerges from alveolar type 1 cells: Rethinking tumorigenesis and clinical implications Jung-Ki Yoon (Seoul National Univ., Korea) 11:10-11:25 Application of lung cancer organoids in precision medicine Jinwook Choi (GIST, Korea)

Session VII (C).
Session VII (B). Biology and novel agents in SCLC		Room B (Grand Ballroom 2)
Date & Time	November 7(Fri), 13:50-14:50
Chair(s)	Hye Ryun Kim (Yonsei Univ., Korea), TBD
Speaker	13:50-14:05 Recent developments in genomics and translational research of SCLC Esra Akbay (University of Texas Southwestern Medical Center, USA) 14:05-14:20 TBD TBD 14:20-14:35 Rethinking radiotherapy in the era of new standards for SCLC Young Seob Shin (Univ. of Ulsan, Korea) 14:35-14:50 New drugs in development for SCLC: In search of new hope Se Hyun Kim (Seoul National Univ., Korea)

Session VII (C).
Session VIII (B). Decoding the tumor microenvironment: A high-tech revolution		Room B (Grand Ballroom 2)
Date & Time	November 7(Fri), 15:05-16:05
Chair(s)	Byoung Chul Cho (Yonsei Univ., Korea), Woong-Yang Park (GxD Inc. & Sungkyunkwan Univ., Korea)
Speaker	15:05-15:20 Latest trend in Multiplex IHC technology for TME research Gil-Je Lee (Akoya biosciences, Inc, Korea) 15:20-15:35 Spatial transcriptomic landscape of NSCLC Yoon Kyung Jwon (Seoul National Univ., Korea) 15:35-15:50 Predicting the TME composition and therapeutic responses using multi-omic technology Woong-Yang Park (GxD Inc. & Sungkyunkwan Univ., Korea) 15:50-16:05 Translating TME research into precision oncology Jong-Eun Park (KAIST, Korea)

Session VII (C).
Closing Symposium (B).		Room B (Grand Ballroom 2)
Date & Time	November 7(Fri), 16:05-16:45
Chair(s)	TBD
Speaker	16:05-16:45 TBD TBD

Session VII (C).
Satellite Symposium III (C).		Room C (Grand Ballroom 1)
Date & Time	November 7(Fri), 08:20-09:00
Chair(s)	TBD
Speaker	TBD TBD

Session VII (C).
Session V (C). Oral Presentation II		Room C (Grand Ballroom 1)
Date & Time	November 7(Fri), 09:10-10:10
Chair(s)	TBD
Speaker	TBD TBD TBD TBD TBD TBD TBD TBD

Session VII (C).
Session VI (C). Oral Presentation III		Room C (Grand Ballroom 1)
Date & Time	November 7(Fri), 10:25-11:25
Chair(s)	TBD
Speaker	TBD TBD TBD TBD TBD TBD TBD TBD

Session VII (C).
Session VII (C). EGFR-Mutant NSCLC: Optimal regimen & rationale		Room C (Grand Ballroom 1)
Date & Time	November 7(Fri), 13:50-14:50
Chair(s)	Jeong-Seon Ryu (Inha Univ., Korea), Grace Dy (Rose Well Park Cancer Institute, USA)
Speaker	13:50-14:05 Mono or Combi, is Two really better than One? Derek De-Rui Huang (National Taiwan University, Taiwan) 14:05-14:20 What should we combine with TKI (Chemo Antibody or ADC) Grace Dy (Rose Well Park Cancer Institute, USA) 14:20-14:35 What is the best sequence for EGFR-Mutant NSCLC? Current options to future options Lyudmila A. Bazhenova (University of California San Diego, USA) 14:35-14:50 Any new treatment options under development in EGFR-Mutant NSCLC currently not approved? Byoung Chul Cho (Yonsei Univ., Korea)

Session VII (C).
Session VIII (C). Multi-omics and AI-driven precision in lung cancer		Room C (Grand Ballroom 1)
Date & Time	November 7(Fri), 15:05-16:05
Chair(s)	Ho Yun Lee (Sungkyunkwan Univ., Korea), Se Hoon Lee (Sungkyunkwan Univ., Korea)
Speaker	15:05-15:20 Multimodal and multi-omics biomedical AI for precision oncology: A comprehensive overview Chan-Young Ock (Lunit, Korea) 15:20-15:35 Multi-omics-based subtyping of NSCLC Hee Sang Hwang (Univ. of Ulsan, Korea) 15:35-15:50 Multi-omics analysis for discovering therapeutic targets in lung cancer Ken Asada (National Cancer Center Research Institute, Japan) 15:50-16:05 LLMs under the microscope: Using it right in medical research and practice Seong Ho Park (National Cancer Center Research Institute, Korea)

Session VII (C).
Joint Symposium with HIRA(Korean) (D). 가이드라인과 급여기준		Room D (Emerald)
Date & Time	November 7(Fri), 09:10-10:25
Chair(s)	이세훈 (성균관의대), 박인규 (서울의대)
Speaker	09:10-09:30 폐암 가이드라인에 나타난 새로운 치료법 이윤규 (성균관의대) 09:30-09:50 폐암 가이드라인에 나타난 새로운 진단법 김태정 (가톨릭의대) 09:50-10:10 최신 치료법이 건강보험에 반영되는 과정 및 가이드라인의 의미 김국희 (건강보험심사평가원) 10:10-10:25 패널토의: 발전적인 급여 등재 과정을 위한 학회와 심평원의 제언 및 논의 이윤규 (성균관의대), 김태정 (가톨릭의대), 김국희 (건강보험심사평가원)

Abstract No.	Presentation Time	Abstract Title	Presenter Name	Affiliation	Country
A-0186	14:45-14:55	Spatial transcriptomics reveals spatially diverse cancer-associated fibroblasts in lung squamous cell carcinoma linked to tumor progression	Kwon Joong Na	Seoul National University	Korea
A-0184	14:55-15:05	Single-cell RNA sequencing revealed that changes in monocytes are involved in the prognosis of durvalumab consolidation therapy following chemoradiotherapy	Duk Ki Kim	Chungnam National University	Korea
A-0105	15:05-15:15	Landscape of tumor heterogeneity and tumor mutational burden (TMB) in non-small cell lung cancer (NSCLC)	Jong Yeob Kim	Feinberg School of Medicine, Northwestern University	USA
A-0127	15:15-15:25	Induction of malignant transformation in human bronchial epithelial cells and lung organoids by chronic exposure to whole cigarette smoke extract	Joo-Eun Lee	Chungnam National University	Korea
A-0057	15:25-15:35	Identification of GREM-1 and GAS6 as specific biomarkers for cancer-associated fibroblasts derived from patients with non-small cell lung cancer	Bo-Guen Kim	Kangbuk Samsung Medical Center	Korea
A-0042	15:35-15:45	Spatially defined co-culture model of non-small cell lung cancer organoids and cancer-associated fibroblasts to investigate phenotypic heterogeneity	Cheol-Kyu Park	Chonnam National University	Korea

Abstract No.	Presentation Time	Abstract Title	Presenter Name	Affiliation	Country
A-0226	09:10-09:20	Perioperative outcomes of neoadjuvant chemoimmunotherapy followed by surgery in stage II-III NSCLC: A real-world study	Junghee Lee	Samsung Medical Center	Korea
A-0214	09:20-09:30	Preliminary analysis of lazertinib consolidation therapy in patients with locally advanced, unresectable, EGFR mutated NSCLC following chemoradiation therapy: PLATINUM trial	Sung Yong Lee	Korea University	Korea
A-0204	09:30-09:40	What Is the Optimal Dose and Fractionation Schedule for Inoperable Node-Negative Large (>5 cm) Non-Small Cell Lung Cancer?	Ye Jin Yoo	Asan Medical Center	Korea
A-0108	09:40-09:50	Double lung transplantation in patients with metastatic lung-limited non-small cell lung carcinoma (NSCLC): A case series	Young Chae	Northwestern University Feinberg School of Medicine	USA
A-0069	09:50-10:00	Normal brain-sparing radiotherapy versus whole brain radiotherapy for multiple brain metastasis from non-small cell lung cancer	Sangjoon Park	Severance Hospital	Korea
A-0046	10:00-10:10	Refining patient selection for prophylactic cranial irradiation in limited-stage small-cell lung cancer: Insights from a Korean multi-institutional cohort study	Hye In Lee	Asan Medical Center	Korea

Abstract No.	Presentation Time	Abstract Title	Presenter Name	Affiliation	Country
A-0080	10:25-10:35	Real-world insights: Treatment patterns and overall survival in patients with small-cell lung cancer in South Korea a single center experience	Sehhoon Park	Samsung Medical Center, Sungkyunkwan University School of Medicine	Korea
A-0196	10:35-10:45	AI-powered pathologic response evaluation of post-neoadjuvant chemoimmunotherapy in NSCLC patients	Kwon Joong Na	Seoul National University	Korea
A-0167	10:45-10:55	Enhanced thrombopoiesis supplies PD-L1 to circulating immune cells via the generation of PD-L1-Expressing platelets in lung cancer patients	Jae Ho Cho	Chonnam National University Medical School	Korea
A-0230	10:55-11:05	Chemotherapy plus immune checkpoint inhibitors in non-small cell lung cancer with actionable gene alterations other than EGFR, ALK, and ROS1	Ji Eun Shin	The Catholic University of Korea St. Vincent's Hospital	Korea
A-0131	11:05-11:15	Sequential hypofractionated radiotherapy followed by anti-PD-L1 atezolizumab for recurrent or refractory small cell lung cancer	Yang-Gun Suh	National Cancer Center	Korea
A-0035	11:15-11:25	Imaging trajectory of transformation into small-cell carcinomas from lung adenocarcinomas undergoing TKI treatment: radiomic prediction	Jihwan Choi	Samsung Medical Center	Korea

Abstract No.	Poster No.	Abstract Title	Presenter Name	Affiliation	Country
A-0215	PE1-01	Engineering precision medicine for lung cancer: Antibody-mimetic scaffolds targeting EGFR	Tushar Kushwaha	All Institute of Medical Sciences	India
A-0128	PE1-02	TP53 mutations in Belarusian patients with non-small cell lung cancer	Hanna Shchayuk	Institute of Genetics and Cytology, National Academy of Sciences of Belarus	Belarus
A-0109	PE1-03	Optimized exosomal miRNA panels for early detection of non-small cell lung cancer	Da Hyun Kang	Chungnam National University	Korea
A-0060	PE1-04	Anticancer effect of Columbianadin against benzopyreneinduced lung cancer in rats: Role of PI3K/Akt/FoxO1 and inflammatory pathway	Vikas Kumar	Sam Higginbottom University of Agriculture, Technology & Sciences	India
A-0047	PE1-05	Role of exosomal proteins in brain-specific metastasis of lung cancer	Dong Ha Kim	Asan Medical Center	Korea
A-0238	PE1-06	The influence of knowledge and attitudes on smoking decisions: Case study of the Pandeyan Boyolai village community, Central Java.	Rinita Istiqomah	Yogyakarta State University	Indonesia
A-0237	PE1-07	Driver genes expression and fusions in patients with lung cancer	Yuliya Stankevich	Institute of Genetics and Cytology of the National Academy of Sciences of Belarus	Belarus
A-0233	PE1-08	Association between long non-coding RNA HOTAIR polymorphism and lung cancer risk: A meta-analysis	Farhana Sultana Mitu	Islamic University	Bangladesh
A-0232	PE1-09	A meta-analytic approach to find the association between polymorphism with in MicroRNAs and lung cancer risk	Md Abdullah Al Maruf	Islamic University	Bangladesh
A-0228	PE1-10	CTSC regulates cell growth in small cell lung cancer via YAP/PAR2 signaling pathway	Nayoung Kim	Chungnam National University Hospital	Korea
A-0208	PE1-11	Lung Organoid to understand mechanism of therapeutic resistance in lung cancer	Jinwook Choi	School of Life Sciences, Gwangju Institute of Science and Technology (gist)	Korea
A-0185	PE1-13	The impact of Living-Donor Lobar Lung Transplantation (LDLLT) procedure on the sexual function of donors and recipients: A systematic review	Rosinta Hotmaida P Purba	The Pranala Institute	Indonesia
A-0179	PE1-14	Loss of Cereblon (CRBN) enhances lung cancer cell migration and invasion through regulation of cystathionine -synthase (CBS)	Kihun Kim	Gwangju Institute of Science and Technology	Korea
A-0173	PE1-15	Parallel Accumulation-Serial Fragmentation for in-depth proteomic analysis of bronchoalveolar lavage fluid of non-small cell lung cancer	Seung Hyeun Lee	Kyung Hee University Medical Center	Korea
A-0164	PE1-16	Butanolic fraction of Asparagus racemosus root alters the JAK/STAT3 Signaling Pathway to mitigate metastasis, apoptosis, and proliferation in lung cancer	Niti Singh	Marlabs Innovation Pvt Ltd.	India
A-0161	PE1-17	Utilizing machine learning methodologies to forecast the occurence of lung cancer in patients of central region.	Manvendra Singh	Hmfa Miet	India
A-0160	PE1-18	Solid Lipid Nanoparticle of Ganodric acid in the treatment against benzopyreneinduced lung cancer in rats: Nrf2/HO-1 signaling pathway	V Kumar	Shalom Institute of Health & Allied Sciences	India
A-0156	PE1-19	Solid lipid nanoparticles of gallic acid enhances apoptosis and proliferation in rats to lessen lung cancer induced by diethylnitrosamine/2-acetylaminofluorene.	Deepika Singh	Shuats	India
A-0154	PE1-20	The incidence of hematologic paraneoplastic syndromes in newly diagnosed lung cancer patients	Roland Helmizar	Baiturrahmah University	Indonesia
A-0114	PE1-22	A pilot study to discover potential early NSCLC biomarkers in the Filipino secretome	Josemaria Alejandro Corpuz	University of the Philippines-Diliman	Philippines
A-0090	PE1-23	Recapitulation tumor microenvionments with lung cancer organoids for drug screening study	Insu Lee	Seoul National University Bundang Hospital	Korea
A-0088	PE1-24	What is our role to reduce lung cancer mortality rates?: Case studies of 7 countries with the highest lung cancer	Nadia Fazira	Andalas University	Indonesia
A-0087	PE1-25	ARAF p.S214C Mutation Enhances Sorafenib Response in Lung Cancer	Carol Lee	The Chinese University of Hong Kong	Hong Kong
A-0076	PE1-27	Enhancing tumoroid applications with regenix in advanced 3D cell culture models	Da Hye Song	Cellartgen	Korea
A-0068	PE1-28	Regenix in lung cancer PDX models: Advancing research and therapeutic potential	Da Hye Song	Cellartgen	Korea
A-0063	PE1-29	Synergistic anticancer effects of Niclosamide and Osimertinib: Repurposing drugs in autophagy for the treatment of EGFR-mutant lung cancer cells	Yuan-Ming Tsai	Tri-Service General Hospital, National Defense Medical Center	Taiwan
A-0051	PE1-30	Identification of Guanine-quadruplex forming DNA aptamer: A promising therapeutic strategy for EGFR overexpressed non-small cell lung cancer	Deepa Singh	All Institute of Medical Sciences	India
A-0050	PE1-31	Austrian biobanking and biomolecular resources research infrastructure - Important partner for research on biological samples	Luka Brcic	Medical University of Graz	Austria
A-0049	PE1-32	Clinical and genomic features of different KRAS Subtypes in non-small cell lung cancer	Soo Han Kim	Pusan National University Hospital	Korea

Abstract No.	Poster No.	Abstract Title	Presenter Name	Affiliation	Country
A-0151	PE1-34	Network pharmacology study revealed the multitargets anticancer mechanism of sesamin in NSCLC	Reny Rosalina	University of Palangka Raya	Indonesia
A-0250	PE1-35	Utilizing machine learning algorithms for enhanced lung cancer diagnosis through imaging biomarkers	Divo Helmizar	Stan Jakarta	Indonesia
A-0239	PE1-36	Deep-learning model for personalized recurrence prediction in early-stage non-small cell lung cancer	Daehwan Lee	Spidercore Inc.	Korea
A-0093	PE1-38	Increased risk of lung cancer in individuals with nontuberculous mycobacterial pulmonary disease: A Korean population-based study	Dongwon Park	Hanyang University Medical Center	Korea
A-0086	PE1-39	Deep-learning-driven prediction of lung cancer recurrence using integrated immune profiling and radiomic features from computed tomography scans	Rifaldy Fajar	Yogyakarta State University	Indonesia

Scientific Program